MiMedx Group, Inc Stock 12‑Month Price Target Cut to $7.2, Implies 82% Upside

MiMedx Group's (MDXG) average price target was reduced from $7.4 to $7.2 by 5 analysts, with a range of $6 to $8. This implies 82% upside from the Oct. 28 closing price. The consensus rating remains 'Buy' across all analysts.

Original reporting
Published Oct 29, 2026, 4:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 4:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
MiMedx Group, Inc Stock 12‑Month Price Target Cut to $7.2, Implies 82% Upside — source image
Decision brief

The 30-second read

Low
01

Why it matters

Analyst target cuts typically lead to short‑term price declines, especially for low‑float stocks.

02

Market read

The target reduction is a modest but actionable piece of news for traders holding or considering MMDX.

03

What to watch

Potential upcoming clinical data or partnership news could offset the target reduction.

Relevance 6/10Novelty 5/10Timing: post‑market today

Background

MiMedx Group is a biotech firm focused on regenerative medicine. The price‑target change comes from a consensus of five analysts.

Market effects

Minimal; the change reflects analyst sentiment on MiMedx rather than a broader sector shift.

None; the news is company‑specific.

Low; limited to investors tracking micro‑cap biotech stocks.

Counterpoint

Some investors may view the still‑large upside as a buying opportunity despite the target cut.

Key entities

  • MiMedx Group, Inc.

    Biotech company whose price target was reduced.

Related articles

$MDXGMed

MiMedx Group Inc (MDXG) (Q3 2026) Earnings Call Highlights: Revenue Jumps 36%

MiMedx Group Inc (MDXG) reported a 36% revenue jump in Q3 2026. CFO Danilo D'Alessandro expects gradual reduction in cash burn over the next four to six quarters. CEO Joe Burnett highlighted growth opportunities in spine laser therapy, with estimated revenue of $13,000 to $20,000 per procedure. The company aims for mid-teens growth in 2027, with guidance expected in January. MDXG also discussed investments in robotics and focused ultrasound, and the status of the UniQure AMT-130 BLA submission.

$MDXGMed

MiMedx (MDXG) Q3 2026 Earnings Call Transcript

MiMedx (MDXG) reported Q3 2026 net sales of $62M, with Surgical revenue up 9% YoY and Wound Care Center volume up 7% sequentially. The company expects to complete the Sanara MedTech acquisition, pending FTC approval, aiming for $400M in combined revenue and 20% adjusted EBITDA margin. MiMedx also won a court ruling against the FDA's classification of AXIOFILL and reached a $25M settlement in a patent infringement case.

$MDXGHighAI 8/10

What MiMedx Group (MDXG) Said on Its Q3 Earnings Call

MiMedx Group (MDXG) reported Q3 earnings with gross profit of $50M, down from $95M YoY, and a GAAP net loss of $9M. Wound care volume rose 20% YoY, but margins declined due to pricing and product mix. The company expects 2027 conditions to persist and anticipates modest EBITDA growth in Q4. MiMedx is acquiring Sanara MedTech, facing FTC review, aiming for $400M revenue and 20% EBITDA margin post-merger. Legal and product updates include a $25M settlement and progress on 510(k) submissions.

$MDXGMed

MiMedx: Q3 Earnings Snapshot

MiMedx Group Inc. (MDXG) reported a Q3 loss of $8.7 million, or 6 cents per share, with adjusted losses of 1 cent per share. Revenue was $62.3 million. The company expects full-year revenue between $250 million and $260 million, according to its earnings release.

$MDXGMed

MIMEDX Announces Third Quarter 2026 Operating & Financial Results Reports Continued Double-Digit Year-Over-Year Volume Growth for Surgical Franchise Delivers…

MIMEDX GROUP, INC. (MDXG) filed an SEC Form 8-K — Results of Operations and Financial Condition. MIMEDX Announces Third Quarter 2026 Operating & Financial Results Reports Continued Double-Digit Year-Over-Year Volume Growth for Surgical Franchise Delivers Wound Care Center Volume Growth Both Sequentially and Year-Over-Year Obtained Favorable Federal Court Ruling in AXIOFILL®